Appln. No.: 10/508,791 Group Art Unit No.: 1621

REMARKS

The claims are 1-27, 29-45, and 49, with claims 1, 22, 29, 39 and 45 being independent. Claims 28, 46-48 and 50-58 have been cancelled without prejudice or disclaimer.

Claims 1-27, 29-45, and 48 were rejected under 35 U.S.C. §103(a) as allegedly unpatentable over US 2004/0072868 (Collins). The Examiner contends that it would have been *prima facie* obvious to make compounds within the generic disclosure of the reference because they are structurally "so similar" to the compounds claimed herein. Applicants respectfully traverse this rejection and respectfully submit that the compounds of the present invention do not fall within the generic disclosure of Collins.

Collins discloses compounds having the following structure:

$$\begin{array}{c} O \\ X \end{array} \begin{array}{c} (CR^1R^2)_p \\ Z \end{array} \begin{array}{c} O \\ CH_2)_n \end{array} \begin{array}{c} B \\ O \\ CHR^4)_q \end{array}$$

wherein for the corresponding $(CR^6R^7)_m$ moiety of the present invention, m is 1, for the corresponding Y moiety of the present invention, Y is O, and for the corresponding W^1 and W^2 substituent of the present invention, W^1 and W^2 (B) are C_{3-8} cycloalkyl or aryl.

Contrary to the Examiner's assertion, Applicants respectfully submit that Collins fails to disclose any compound wherein W¹ is a heteroaryl moiety, any compound wherein W² and W³ are H, any compound wherein m is 0, or any compound wherein Y is S, NR¹² or CR⁴R⁵. Moreover, Collins fails to provide any motivation to make such compounds.

Withdrawal of this Section 103 rejection is respectfully requested.

In view of the foregoing amendments and remarks, Applicants respectfully submit that the subject application is in condition for allowance. If the Examiner has any remaining objections or concerns, the Examiner is respectfully requested to contact Applicants' undersigned attorney to resolve such issues and advance the case to issue.

Appln. No.: 10/508,791 Group Art Unit No.: 1621

Authorization is hereby provided to charge any fees under 37 C.F.R. §1.16 or §1.17 which may be required to obtain consideration of this submission to Deposit Account No. 19-2570.

Respectfully submitted,

/KathrynLSieburth/

Kathryn L. Sieburth Attorney for Applicants Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\KLS\Cases\P51327\\Natl Stage\RCE\RCE ROA 1 6-21-06.doc